Home
 /
Papers
 /
Cell Biology
 /
Interorganelle competition for linoleic acid underlies steatotic liver pathology
Preprint
Open access
V1
Top 1% · Validated by QED

Interorganelle competition for linoleic acid underlies steatotic liver pathology

Chuanhai Zhang, Dengbao Yang, Hiroyuki Suzuki +17 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.01.11.698890
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cell Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that lipid droplets actively outcompete mitochondria for linoleic acid via CLSTN3B-stabilized ER-LD bridges, this work overturns the view of lipid droplets as passive buffers and reframes them as drivers of mitochondrial dysfunction and disease.

QED claims analysis

Summary

Diet-induced hepatic expression of CLSTN3B drives MASLD pathology by stabilizing ER-LD membrane bridges that preferentially sequester linoleic acid into lipid droplet triacylglycerides, thereby depleting mitochondrial linoleic acid required for cardiolipin maturation and causing mitochondrial dysfunction, oxidative stress, and progressive liver injury.

See full analysis
Main Claim 1 –

Caloric overload induces hepatocyte CLSTN3B via PPARγ activation

Supporting evidence

  • PPARγ binds CLSTN3B promoter to drive diet-induced transcription
Main Claim 2 –

CLSTN3B R-rich segment promotes lipid droplet biogenesis and storage

Supporting evidence

  • CLSTN3B loss diverts lipids to oxidation, increasing energy expenditure
  • CLSTN3B overexpression promotes hepatic steatosis via R-rich segment
Main Claim 3 –

Hepatic CLSTN3B drives steatohepatitis, fibrosis, and liver injury

Main Claim 4 –

CLSTN3B diverts linoleic acid from mitochondria, impairing cardiolipin

Supporting evidence

  • CLSTN3B ablation improves mitochondrial function and lowers oxidative stress
  • CLSTN3B enriches linoleoyl phosphatidic acid at ER–LD junctions
  • Linoleic acid enhances CLSTN3B-dependent ER–LD phospholipid exchange
  • CLSTN3B R-rich peptide preferentially mixes linoleoyl-containing membranes
  • CLSTN3B directs linoleic acid to lipid droplets and expansion
  • CLSTN3B-driven lipid droplet growth depletes mitochondrial linoleic acid

Abstract

Lipid droplets (LDs) are traditionally viewed as protective organelles that sequester potentially cytotoxic lipids. However, whether and how LD biogenesis in pathological contexts actively rewires interorganelle lipid homeostasis to drive organelle dysfunction and disease progression remains unexplored. Here, we identify the adipocyte-enriched protein calsyntenin 3β (CLSTN3B) as a critical promoter of metabolic dysfunction-associated steatotic liver disease (MASLD). CLSTN3B, an ER-LD contact protein previously shown to support LD maturation in adipocytes, is robustly induced in mouse hepatocytes by peroxisome proliferator-activated receptor γ (PPARγ) in response to dietary caloric overload. CLSTN3B drives LD biogenesis and neutral lipid storage by stabilizing hemifusion-like ER-LD membrane bridges via its arginine-rich segment. These bridges preferentially recruit cone-shaped linoleoylated phosphatidic acid (PA), diverting linoleic acid (LA) into triacylglycerides (TAGs) rather than mitochondrial cardiolipin (CL), leading to disrupted cristae architecture, deficient ETC supercomplex assembly, elevated electron leak, and oxidative stress. Hepatocyte-specific CLSTN3B deletion impairs LD formation, reduces TAG accumulation, enhances fatty acid oxidation, restores CL maturation, and mitigates oxidative stress, collectively attenuating MASLD progression. Consistently, hepatic CLSTN3B expression correlates with fibrosis severity and progression in human MASLD. These findings position LDs as active regulators of interorganelle lipid partitioning and establish CLSTN3B as a key determinant of mitochondrial vulnerability, providing a general framework for how dysregulated organelle interfaces shape disease.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?